- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01229774
Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty
Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty, a Prospective, Double Blind, Phase III Study
The primary aim of this study is to test if etoricoxib decreases the perioperative blood loss compared to diclofenac.
Secondary questions to be explored are:
- Does etoricoxib prevent Heterotopic ossification after Total Hip Arthroplasty as well as diclofenac ?
- Do diclofenac and etoricoxib both reduce pain at rest and on movements?
- Does etoricoxib compared to diclofenac reduce the amount of rescue medication (Oxycodon)?
- Does etoricoxib improve gastrointestinal tolerability compared to diclofenac?
Study Overview
Status
Intervention / Treatment
Detailed Description
Total Hip Arthroplasty (THA) is a common surgical procedure in orthopaedic surgery which can be associated with perioperative blood loss and severe postoperative pain. Adequate pain management is very important to achieve early mobilisation in order to avoid immobility-induced complications. Non steroidal antirheumatic agents (NSAIDs) as selective Cox-2 inhibitors are commonly used in the management of postoperative pain. There exist non-selective and selective Cox-inihibitors. Non-selective NSAIDs block the systhesis of prostagandins by the two iso-enzymes of the cyclooxygenase, Cox-1 and Cox-2. For this reason the bleeding risk after operations (e.g.tonsillectomy) is increased.
In this regard, the perioperative use of Cox-2 selective NSAIDs is advantageous for pain management after tonsillectomy. This could be shown for Rifecoxib, a selective Cox-2 inihibitor. For THAs with treatment of Etoricoxib, also a selective Cox-2 inhibitor, possible complications as the increased risk of haematoma, gastrointestinal bleeding and the need of blood transfusion could possibly be reduced. Selective Cox-2 inhibitors do not interfere with the coagulation system. Study results show that other selective Cox-2 inhibitors like meloxicam reduce perioperative blood loss. Thus, besides ensuring a good perioperative pain management, selective Cox-2 inhibitors may in addition cause less blood loss than non-selective NSAIDs.This possible reduction of blood loss during pain management with Etoricoxib (Arcoxia) will be investigated the described clinical trial.
Heterotopic ossification (HO) is a complication occurring after THA which can lead to postoperative pain and reduced function. Non-selective NSAIDs are commonly used in the prophylaxis of heterotopic ossifications after THA. The exact mechanism of prevention of bone formation is unclear. Some results indicate that the development of HO follows a Cox-2 pathway. A further aim of this clinical trial is to investigate the efficacy of Etoricoxib in the prevention of heterotropic ossification.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Bavaria
-
Bad Abbach, Bavaria, Germany, 93077
- Department of Orthopedic Surgery
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Indication for THA because of primary and secondary osteoarthritis of the hip.
- male or female patients of the age of 55 - 85 years
- informed consent afer having been informed in detail about the clinical trial by the investigator
- negative pregnancy test (<= 2 days before inclusion) for women with child bearing potential (pre menopausal, <2 years menopausal, not surgically sterile), use of high security contraception methods as oral contraception agents or preservatives. The use of high security conception methods is also to obligatory for male patients
Exclusion Criteria:
- Known hypersensitivity to one of the two investigational medical products or substaces of similar chemical structure or to any of the excipients
- Patients who have experienced bronchospasm, asthma, acute rhinitis, urticaria, or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors
- unexplained dysfunction of haematopoiesis
- treatment with NSAIDs or coxiben in the past 5 days before start of study
- Active peptic ulceration or active gastro-intestinal (GI) bleeding
- Pregnancy and lactation
- Congestive heart failure (NYHA II-IV)
- Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease
- clinically relevant disease of the cardiovascular system, severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10), severe renal dysfunction (estimated renal creatinine clearance <30 ml/min, clinical relevant disease of the nervous system, the endocrinium or another severe systematic disease
- Systemic lupus erythematodes or mixed connective tissue disease
- Inflammatory bowel disease
- alcohol or drug abuse during the last past 3 months
- Patients with hypertension BP persistently > 140/90mmHG) and has not been adequately controlled
- life expectancy <6 months
- state of mind which does not enable the patient to understand the nature of the study, its importance and possible consequences
- evidence that the respective person will not cooperate with the study protocoll
- participation of the patient in another clinical trial during the past 4 weeks before inclusion
- prior participation in this clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Diclofenac
|
Voltaren Resinat 75mg once a day on day -1 and 0 in the evening; twice a day (in the morning and in the evening) days 1-7
|
EXPERIMENTAL: Etoricoxib
|
Arcoxia 90 mg once a day in the evening day -1 and 0 and once a day in the morning days 1-7 plus on tablett of placebo every evening
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Perioperative blood loss after implantation of a hip joint endoprosthesis
Time Frame: Three days
|
The primary objective of the study is the designation of the perioperative blood loss after implantation of a hip joint endoprosthesis under the influence of Etoricoxib or of Diclofenac.
The expectations hypothesis is that under Etoricoxib patients will loose a smaller quantity of blood than under Diclofenac.
|
Three days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Heterotopic ossification
Time Frame: six months
|
The secondary objectives are to investigate whether after hip joint endoprosthesis Etoricoxib can prevent heterotopic ossification in equal measure as Diclofenac
|
six months
|
Postoperative pain
Time Frame: nine days
|
It will be investigated if Diclofenac and Etoricoxib effectively reduce postoperative pain after hip joint endoprosthesis at rest and during movement.
|
nine days
|
Reduction of rescue medication
Time Frame: nine days
|
It will be investigated whether Etioricoxib can reduce the use of rescue-medication as compared to Diclofenac
|
nine days
|
Gastroinstestinal tolerance
Time Frame: nine days
|
It will be investigated if the gastrointestinal tolerance of Etoricoxib is superior to the one of Diclofenac
|
nine days
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Osteoarthritis, Hip
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Diclofenac
- Etoricoxib
Other Study ID Numbers
- Eto-Dic-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coxarthrosis
-
University Hospital, BrestRecruitingCoxarthrosis; Primary | Coxarthrosis; SecondaryFrance
-
Aesculap AGRecruitingCoxarthrosis; PrimaryCzechia
-
Istituto Ortopedico RizzoliWithdrawnCoxarthrosis; PrimaryItaly
-
Lille Catholic UniversityNot yet recruiting
-
Smith & Nephew Orthopaedics AGCompletedPrimary and Secondary Coxarthrosis | Dysplasia Coxarthrosis | Post-traumatic Necrosis of the Femoral HeadGermany
-
Ankara City Hospital BilkentCompletedCoxarthrosis; PrimaryTurkey
-
TRB Chemedica AGRecruiting
-
Bezmialem Vakif UniversityUnknown
-
Ullevaal University HospitalHelse Sor-Ost; Ringerike hospital HF, Hønefoss Norway; Ortomedic AS, Lysaker...Unknown
-
Northern Orthopaedic Division, DenmarkCompleted
Clinical Trials on Etoricoxib
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Radboud University Medical CenterCompletedOssification, HeterotopicNetherlands
-
Organon and CoCompleted
-
Clinica Virgen MilagrosaMerck Sharp & Dohme LLCTerminatedSoft Tissue Injuries of the Shoulder | Tenosynovitis and Bursitis Affecting the ShoulderPeru
-
Núcleo de Estudos em Esportes e Ortopedia, BrazilMerck Sharp & Dohme LLCUnknownSprains and Strains | ContusionsBrazil
-
University of Erlangen-Nürnberg Medical SchoolMerck Sharp & Dohme LLC; Rush University Medical Center; HELIOS Kliniken GmbHTerminatedPain | Postoperative Pain | Osteoarthritis, HipGermany
-
Organon and CoCompletedAcute Pain Following a Total Abdominal Hysterectomy